YH32364

YH32364 · Yuhan Corporation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for YH32364, covering 2025-08-01 to 2025-08-01. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors [Phase 1, Phase 2]

See pricing